UBX stock icon

Unity Biotechnology
UBX

$1.51
0%

Market Cap: 25.4M

 

About: Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Employees: 19

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

209% more call options, than puts

Call options by funds: $71K | Put options by funds: $23K

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

4.36% less ownership

Funds ownership: 25.69% [Q4 2023] → 21.33% (-4.36%) [Q1 2024]

5% less funds holding

Funds holding: 40 [Q4 2023] → 38 (-2) [Q1 2024]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

29% less capital invested

Capital invested by funds: $8.33M [Q4 2023] → $5.87M (-$2.45M) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
430%
upside
Avg. target
$8
430%
upside
High target
$8
430%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
430%upside
$8
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Andrew Fein
430%upside
$8
Buy
Maintained
16 Apr 2024

Financial journalist opinion